Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep 1;110(9):2198-2202.
doi: 10.3324/haematol.2024.286864. Epub 2025 Mar 20.

Dissecting CD47 expression in lymphoid neoplasms to inform precision immunotherapy with anti-CD47 phagocytic checkpoint blockade

Andrea Marra  1 , Alan Ramsay  2 , Samuel Chamberlain-Keene  3 , Gabriela Soares  2 , Maurilio Ponzoni  4 , Sugerdana Padmasri  5 , Manuel Rodriguez-Justo  2 , Sabine Pomplun  2 , Ian Proctor  2 , Anna Childerhouse  2 , Alsharabati Muntasser  5 , Mario Cioce  6 , Vito Michele Fazio  6 , German Ott  7 , Miguel Piris  8 , Brunangelo Falini  9 , Teresa Marafioti  10
Affiliations

Dissecting CD47 expression in lymphoid neoplasms to inform precision immunotherapy with anti-CD47 phagocytic checkpoint blockade

Andrea Marra et al. Haematologica. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
CD47 expression in small B-cell non-Hodgkin lymphomas. CD47 is consistently expressed on neoplastic B cells in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (A), and mantle cell lymphoma (MCL) (B); about 40% of follicular lymphomas (FL) are positive for CD47, as the case here shown (C); FL with marginal zone differentiation (MZD) shows positive CD47 staining of the marginal zone compartment, while CD47 is negative on neoplastic B cells (D); in pediatric-type FL, neoplastic B cells are negative for CD47 expression (E). In marginal zone lymphoma (MZL) (F-H), strong CD47 expression is detected on neoplastic B cells within the lymph node (F), or extra-nodal sites (G), including the spleen (H). Scale bars, 100 μm.
Figure 2.
Figure 2.
CD47 expression in Hodgkin and high-grade B-cell non-Hodgkin lymphomas. Strong positive membranous/cytoplasmic staining of CD47 in classical Hodgkin lymphoma (HL) (A). In classical HL, CD47 is expressed both on Hodgkin/Reed-Sternberg cells (A), identified by CD30 expression (B), and on reactive small mature lymphocytes and macrophages infiltrating the exuberant tumor microenvironment (A). In nodular-lymphocyte predominant HL, CD47 expression is absent on sparse lymphocyte predominant tumor cells (“popcorn” cells), characterized by large, lobulated nuclei and variable sized nucleoli, but can be detected on background small mature lymphocytes and scattered macrophages in the tumour microenvironment (C). CD47 expression on tumor B cells in Burkitt lymphoma (D), germinal center (GC) (E) and non-germinal-center (non-GC) (F) subtypes of diffuse large B-cell lymphoma (DLBCL). Genetic and clinical data from patients with DLBCL were retrieved from the GDC NCI-CCR-DLBCL dataset (https://xenabrowser.net/) and dichotomized after median CD47 mRNA expression (G): left histogram, distribution of activated B-cell-like (red) and GC-like (green) genetic subtypes within the CD47-high and CD47-low subsets of DLBCL; right histogram, distribution of BCL6 fusions and NOTCH2 mutations (BN2, purple), EZH2 mutations and BCL2 translocations (EZB, blue), MYD88L265P and CD79B mutations (MCD, orange) and NOTCH1 mutations (N1, brown) seeds according to median CD47 expression in DLBCL. Scale bars, 100 μm.
See this image and copyright information in PMC

References

    1. Majeti R, Chao MP, Alizadeh AA, et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell. 2009;138(2):286-299. - PMC - PubMed
    1. Marra A, Akarca AU, Martino G, et al. CD47 expression in acute myeloid leukemia varies according to genotype. Haematologica. 2023;108(12):3491-3495. - PMC - PubMed
    1. Chao MP, Alizadeh AA, Tang C, et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell. 2010;142(5):699-713. - PMC - PubMed
    1. Advani R, Flinn I, Popplewell L, et al. CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin’s lymphoma. N Engl J Med. 2018;379(18):1711-1721. - PMC - PubMed
    1. Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: lymphoid neoplasms. Leukemia. 2022;36(7):1720-1748. - PMC - PubMed

LinkOut - more resources